Insider buying last 90 days
No open-market insider purchases were filed for ELV in the last 90 days.
From Form 4 filings, dated to when each was filed.
Every ELV insider filing, plotted on the chart in Gekko.Open ELV in Gekko
NYSE: ELV
Elevance Health (ELV) Stock Analysis & Forecast
Nov 4 close
$434.18+20.43 (+4.9%)
Gekko Brief
Nov 4 closeElevance Health closed at $434.18 on 4 November 2026, +4.9% on the day. The price sits above both the 50-day ($411.75) and 200-day ($373.04) moving averages, inside a 52-week range of $274.84 to $450.69. The GekkoIndex reads 52.8, in the Neutral zone, down 4.4 points over five sessions. Gekko Fair Value is $635.19, so the price is 31.6% below it.
The next earnings report is due on 27 January 2027, 83 days away (before open). Over the last 8 reports the company beat the earnings estimate 6 times, with an average move of 7.1% across the report. Seasonally, the next 20 trading days from this point averaged +0.4% over the last 5 years, rising in 2 of them.
13 firms rate the stock: 9 buy, 4 hold and 0 sell, with a consensus target of $482.38. A typical daily move is about 3.1%, and a typical 20-day move about 4.5%. On the swing-trade checklist, 3 items read supportive and 0 read as a headwind.
A plain summary of the figures as of the Nov 4, 2026 close.
Elevance Health price vs fair value
Close $434.18200-day averageGekko Fair Value $635.19
Elevance Health quick facts
- Market cap
- $94.16B
- P/E ratio
- 17.6
- Forward P/E
- 14
- EPS, TTM
- $23.55
- Revenue, TTM
- $201.8B
- Profit margin
- 2.6%
- Dividend yield
- 1.64%
- Beta
- 0.63
- Volume
- 1.73M avg 1.45M
- 1-year return
- +38.6%
- Typical daily move
- ±3.1%
- Typical 20-day move
- ±4.5%
- 50-day average
- $411.75
- 200-day average
- $373.04
- Next earnings
- Jan 27 before open
- Shares outstanding
- 216.9M
Elevance Health swing-trade checklist
Elevance Health scores 3 supportive, 2 mixed and 0 headwinds across the 5 checklist items with data.
Six things swing traders check before a 20-day hold, read from the latest data.
3 supportive2 mixed0 headwinds
- Trendsupportive
Above 50 and 200-day
Close $434.18 is above the 50-day ($411.75) and 200-day ($373.04) averages, and the 50-day is above the 200-day.
See the chart - GekkoIndexmixed
52.8, Neutral
Reading 52.8 is in the Neutral zone.
See the GekkoIndex - Fair valuesupportive
31.6% below
Price is 31.6% below Gekko Fair Value (more than 5% below).
See fair value - Smart moneyno data
No data
No insider, Congress or unusual options activity in the window.
See smart money - Earnings risksupportive
Reports in 83 days
Next report Jan 27, 2027, 83 days away — outside a typical 20-trading-day hold.
See earnings - Seasonalitymixed
+0.4% on average
From this point in the calendar, the next 20 trading days averaged +0.4% over 5 years, rising in 2 of them.
See seasonality
A description of current data, not a recommendation. How this page works
Elevance Health stock chart and price history
Elevance Health closed at $434.18 on Nov 4, 2026, +38.6% over the past year, inside a 52-week range of $274.84 to $450.69.
Close50-day average200-day averageVolume
Use the left and right arrow keys to read daily values.
Performance Breakdown
- 1 month
- +8.5%
- 3 months
- +10.9%
- 6 months
- +15.9%
- 1 year
- +38.6%
The full ELV chart adds GekkoIndex, insider, options, Congress and hedge fund markers, plus TrendCandles™.Open ELV in Gekko
Follow Elevance Health through every session
Put ELV on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.
Track ELV in GekkoFree for 7 days. No credit card required.
About Elevance Health
Elevance Health works as a health benefits organization, helping people, families and communities navigate their health and wellness needs. It connects roughly 118 million individuals with care, support and resources aimed at helping them live healthier lives. Its reach spans medical coverage, digital health tools, pharmacy services, behavioral health support and clinical care solutions.
The company brings together a range of health-related services under one roof, addressing different aspects of a person's wellbeing rather than a single type of care. Its customer base is broad, serving individuals and families who rely on it for various forms of health assistance and coverage.
Elevance Health was founded in 1944 and is headquartered in Indianapolis, Indiana. It took on its current name in June 2022, having previously been known as Anthem, Inc. Its shares are listed on the NYSE under the ticker ELV.
- Listed
- NYSE
- Sector
- Health services
- Industry
- Managed health care
- Website
- elevancehealth.com
Elevance Health GekkoIndex: the smart money zone
Elevance Health’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 52.8, in the Neutral zone, down 4.4 points over five sessions.
52.8Neutral
Down 4.4 points over five sessions.
Reading for Nov 4, 2026
What followed past readings in each zone
| Zone | Readings | 5 days | 20 days | ||
|---|---|---|---|---|---|
| Buying | 36 | −0.3% | −2.7% | ||
| Accumulation | 226 | −0.2% | −0.6% | ||
| Neutral (current zone) | 388 | +0.2% | +0.5% | ||
| Distribution | 45 | +0.2% | +1.2% | ||
| Selling | 2 | Too few readings yet | |||
Average ELV share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Neutral readings averaged +1.0% over 20 days. Past behaviour doesn’t guarantee future results.
Neutral zone: No clear directional signal. About the five zones →
See every daily GekkoIndex reading plotted over the ELV price, zone by zone.Track ELV in Gekko
Is Elevance Health stock overvalued? Gekko Fair Value
Elevance Health trades 31.6% below Gekko Fair Value of $635.19, so the shares are undervalued on Gekko’s estimate.
Gekko’s own estimate of what Elevance Health shares are worth, recalculated every trading day.
$635.19
Gekko Fair Value, Nov 4, 2026
31.6% Undervalued
At the end of Aug 2026 the price was 42.5% below the estimate.
Gekko Fair ValueShare price, month end
Gekko Fair Value on every chart, with the gap to price updating daily.Open ELV in Gekko
Elevance Health insider and Congress trading
No open-market insider purchases were filed for Elevance Health, and no Congress trades were disclosed, in the last 90 days.
Plus buybacks, unusual options and fund positions, each dated to when it became public.
Congress trades last 90 days
No trades in ELV were disclosed by members of Congress in the last 90 days.
From congressional disclosures, which report amounts as ranges.
Congress disclosures for ELV, plotted on the chart in Gekko.Open ELV in Gekko
Buybacks
Elevance Health has been buying back its own shares.
- Bought back, quarter ended Sep 30, 2026
- $330.0M
- As a share of market cap
- 0.35%
- Trailing four quarters
- $2.16B
From company filings.
Hedge funds and billionaires quarter ended Jun 30
1of the funds Gekko tracks holds ELV.
0added1opened0trimmed2sold out
Which funds are on each side, name by name.Unlock in Gekko
Elevance Health earnings: next date and track record
Elevance Health reports on Jan 27, 2027, before the open (83 days away), and beat the EPS estimate in 6 of its last 8 reports.
Next earnings report
Jan 27, 2027
Expected before the open, 83 days away
- EPS estimate
- $2.08
- Revenue estimate
- $49.38B
6 of 8reports beat the EPS estimate
±7.1%average move across the report
5 of 8reports followed by a gain
Share-price move across each report
Last earnings call, Oct 21, 2026 AI summary
- What they said
- Elevance Health reported strong Q3 2026 results with outperformance across Medicaid, Medicare Advantage, and Individual ACA segments. The company raised 2026 adjusted EPS guidance to at least $29 and increased the earnings baseline to at least $26.75. Carelon's oncology solution reduced avoidable inpatient admissions by 15%, and the Elevate platform identified over $300 million in anticipated savings. Medicaid margins tracked ahead of guidance following rate actions.
- Guidance
- 2026 adjusted diluted EPS guidance raised to at least $29, with baseline of at least $26.75. Management expects at least 12% adjusted EPS growth in 2027, driven by health benefits margin improvement, Carelon expansion, and operating efficiency gains.
| Reported | EPS | Revenue | Move |
|---|---|---|---|
| Oct 21, 2026 | $6.99 est $4.71 | $50.44B est $49.28B | +1.2% |
| Jul 15, 2026 | $7.45 est $6.18 | — est $48.82B | −12.6% |
| Apr 22, 2026 | $12.58 est $10.81 | $49.49B est $48.20B | +5.5% |
| Jan 28, 2026 | $3.33 est $3.10 | $49.31B est $49.84B | +7.5% |
| Oct 21, 2025 | $6.03 est $4.93 | $50.71B est $49.38B | −2.5% |
| Jul 17, 2025 | $8.84 est $8.91 | $49.78B est $48.19B | −19.6% |
| Apr 22, 2025 | $11.97 est $11.41 | $48.89B est $46.30B | +5.0% |
| Jan 23, 2025 | $3.84 est $3.85 | $45.44B est $44.95B | +2.6% |
“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.
Elevance Health stock forecast and analyst price targets
Analysts’ average 12-month price target for Elevance Health is $482.38, +11.1% from the last close, from 13 firms rating the stock in the last 90 days.
$482.38consensus 12-month target, +11.1% from the last close
Now $434.18Avg $482.38
Low $406High $523
Each firm’s latest rating in the last 90 days: 13 firms.
Latest analyst actions
| Date | Firm | Target | vs price |
|---|---|---|---|
| Oct 27 | Wells Fargo | $492 | +13.3% |
| Oct 23 | Mizuho Securities | $490 | +12.9% |
| Oct 23 | TD Cowen | $495 | +14.0% |
| Oct 22 | Bank of America Securities | $500 | +15.2% |
| Oct 22 | Morgan Stanley | $449 | +3.4% |
+0.5%average 20-day move after past Neutral readings
+0.4%average move over the next 20 trading days in the last 5 years
±3.1%typical daily move, from the 14-day average range
Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.
Elevance Health seasonality: the next 20 trading days
Over the next 20 trading days from Nov 4, Elevance Health averaged +0.4% across the last 5 years, rising in 2 of them.
Next 20 trading days, by year
Average move and hit rate
| Window | Average | Years higher |
|---|---|---|
| Next 5 trading days | −0.3% | 3 of 5 |
| Next 10 trading days | −0.8% | 3 of 5 |
| Next 15 trading days | +1.1% | 2 of 5 |
| Next 20 trading days | +0.4% | 2 of 5 |
| Next 30 trading days | +0.4% | 3 of 5 |
For scale, ELV’s typical 20-trading-day move in either direction is about 4.5%.
Elevance Health market cap and key statistics
Elevance Health’s market cap is $94.16B, with a P/E ratio of 17.6 and revenue of $201.8B over the last twelve months.
Valuation
- Market cap
- $94.16B
- P/E ratio
- 17.6
- Forward P/E
- 14
- EPS, TTM
- $23.55
- Gekko Fair Value
- $635.19
Trading
- Volume
- 1.73M
- Avg volume, 20 days
- 1.45M
- 52-week high
- $450.69
- 52-week low
- $274.84
- Shares outstanding
- 216.9M
Financials
- Revenue, TTM
- $201.8B
- Profit margin
- 2.6%
- Return on equity
- 11.5%
- Quarterly earnings growth, YoY
- +17.9%
Risk and income
- Beta
- 0.63
- Typical daily move
- ±3.1%
- Typical 20-day move
- ±4.5%
- Dividend yield
- 1.64%
Elevance Health stock news this week
Coverage of Elevance Health this week reads positive: 7 positive, 4 neutral and 3 negative headlines.
- CVS Tumbles 12% on Plan to Split Into Two Companies Despite Earnings Beat; Elevance Health Rises 4%, Cigna Climbs 3%24/7 Wall St., Nov 4
- Elevance Health stock: Wells Fargo lifts target to USD 492ad-hoc-news.de, Nov 4
- Elevance Health stock: Wells Fargo lifts target as Medicaid trends improvead-hoc-news.de, Nov 3
- Elevance Health Inc (A58.MU) Seasonal returns chartYahoo Finance UK, Nov 3
- Fund Update: 181,109 ELEVANCE HEALTH (ELV) shares added to ACR Alpine Capital Research, LLC portfolioQuiver Quantitative, Nov 2
- Elevance Health Inc. stock outperforms competitors despite losses on the dayMarketWatch, Nov 2
Elevance Health peers
Elevance Health’s 6 largest industry peers by market value, with today’s move, GekkoIndex zone and gap to Gekko Fair Value.
| Stock | GekkoIndex zone | vs Fair Value |
|---|---|---|
| UNHUnitedHealth | Neutral | 9.7% above |
| CICigna | Neutral | 33.1% below |
| HUMHumana | Neutral | 22.1% below |
| CNCCentene | Neutral | 13.6% below |
| MOHMolina Healthcare | Neutral | 34.2% below |
| OSCROscar Health | Neutral | 4.8% above |
A peer links to its own page where one exists.
Elevance Health stock FAQ
What is Elevance Health’s market cap?
Elevance Health’s market cap is $94.16B at the Nov 4, 2026 close of $434.18, with 216.9M shares outstanding. The shares trade on a P/E ratio of 17.6.
What is the Elevance Health stock forecast?
The consensus analyst 12-month price target for Elevance Health is $482.38, +11.1% from the last close. Of the 13 firms that rated the stock in the last 90 days, 9 rate it a buy, 4 a hold and 0 a sell. Gekko doesn’t publish price predictions of its own.
Is Elevance Health stock overvalued or undervalued?
On Gekko’s estimate Elevance Health is undervalued: the Nov 4, 2026 close of $434.18 is 31.6% below Gekko Fair Value of $635.19. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.
When does Elevance Health report earnings next?
Elevance Health is expected to report on Jan 27, 2027, before the market opens (83 days away). Analysts expect earnings of $2.08 per share on revenue of $49.38B. Elevance Health beat the earnings estimate in 6 of its last 8 reports, moving 7.1% on average across the report.
What is Elevance Health’s 52-week high and low?
Elevance Health’s 52-week high is $450.69 and its 52-week low is $274.84; it closed at $434.18 on Nov 4, 2026, +38.6% over the past year. Over the last five years the shares peaked at $567.26 on Sep 3, 2024.
Is Elevance Health stock a buy right now?
Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 3 of the 5 items with data read as supportive (trend, fair value and earnings risk), 2 as mixed (gekkoindex and seasonality). The checklist is a description of current data, not a recommendation.
How this page works
During US trading hours the price at the top of the page is a delayed quote, refreshed every 15 minutes; everything else is rebuilt after each US market close. The GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →
See Elevance Health the way Gekko members do
Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.
Join 1,461 other traders using Gekko
Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.